CSI Market
Sign In | Register

Pressure Biosciences Inc (PBIO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PBIO Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Pressure Biosciences Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2024)
6 Months 		(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Operating Activities
Income-15.19
Depreciation & amortization0.17
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.11
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.63
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Common Stock Isued To Vendors-
Amortization Of Third Party Fees Paid In Restricted Common Stock-
Change In Fair Value Of Warrant Derivative Liability-
Amortization Of Third Party Fees Paid In Common Stock And Warrants-
Embedded Derivative Gain On Embedded Derivative-
Accretion Of Interest And Amortization Of Debt Discount-
Common Stock Issued For Debt Extension0.11
Gain On Extinguishment Of Liabilities-
Warrants Issued For Service-
Impairment Loss On Investment-
Issuance Of Stock For Services-
Operating Lease Right Of Use Asset Amortization Expense-
Common Stock Issued For Interest And Extension Fees-
Lossgain On Extinguishment Of Accrued Liabilities And Debt-
Accretion Of Discount On Loan Receivable-
Gain On Loan Forgiveness-
Change In Operating Lease Rightofuseasset-
Gains On Extinguishment Of Debt-
Noncash Lease Expense0.01
Debt And Equity Securities Realized Gain Loss0.00
Increase Decrease In Operating Lease Liability-0.01
Income taxes0.00
Gain (Loss) on Investments0.00
Accounts Receivable0.22
Increase (Decrease) in Accounts Payable-0.17
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities2.15
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.09
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities9.31
Discontinued operations0.00
Net Cash flow from Operating Activities-2.57
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings3.33
Long-term debt - repayments-0.84
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Net Proceeds From Stock Warrant Exercise-
Restricted Cash-
Investment Income Interest And Dividend-
Proceeds From Issuance Of Series J Convertible Preferred Stock-
Payments On Convertible Debt-
Funds Held For Private Placement-
Dividends Preferred Stock Stock-
Net Proceeds From Warrant Reset Transaction-
Payment Of Prepayment Penalty-
Payments On Prepayment Penalty-
Payments On Nonconvertible Debt Related Party-
Proceeds From Non Convertible Debt-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.50
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.57
Total Cash Flow-0.07
4 historic quarters locked

Sign in to unlock the full Pressure Biosciences Inc cash flow history.

Sign In Create Free Account

About Pressure Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20240630)
  • Filed with the SEC: February 7, 2025
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-25-005468

Figures are derived from filed reports and may be restated. Historical data is subject to revision.